 The FDA has placed a partial clinical hold on Curis Incs NASDAQ: CRIS TakeAim Leukemia Phase 12a study in relapsed or refractory RR acute myeloid leukemia AML or high-risk myelodysplastic syndrome MDS. The TakeAim Leukemia study is evaluating emavusertib CA-4948. 